Rituximab (Rituxan) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard induction therapy for patients with advanced-stage diffuse large B-cell lymphoma, including both elderly and younger patients.
Jerry Ingram
Advertisement
Articles by Jerry Ingram
For clinicians, MRI may offer a more in-depth view than mammography for planning surgery and screening for contralateral breast cancers, but does use of MRI actually benefit patients?
Advertisement
Latest Updated Articles
- R-CHOP is standard of care for advanced DLBCL patients
Published: November 1st 2007 | Updated:
- Preop MRI for breast cancer: Intuition no substitute for data
Published: November 1st 2007 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
3
What Do Physicians and Patients Think About ADCs as Cancer Treatment?
4
Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma
5
